Arcturus Therapeutics Holdings Inc (ARCT)
16.91
-0.16
(-0.94%)
USD |
NASDAQ |
Nov 22, 16:00
16.94
+0.03
(+0.18%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Cash from Financing (Quarterly): 0.693M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.693M |
| June 30, 2024 | 2.403M |
| March 31, 2024 | 2.188M |
| December 31, 2023 | -18.66M |
| September 30, 2023 | 21.84M |
| June 30, 2023 | 0.094M |
| March 31, 2023 | -27.36M |
| December 31, 2022 | -2.232M |
| September 30, 2022 | -1.22M |
| June 30, 2022 | 0.257M |
| March 31, 2022 | 0.336M |
| December 31, 2021 | 0.23M |
| September 30, 2021 | 0.692M |
| June 30, 2021 | 0.082M |
| March 31, 2021 | 47.01M |
| December 31, 2020 | 163.20M |
| September 30, 2020 | 187.22M |
| June 30, 2020 | 85.60M |
| March 31, 2020 | 0.118M |
| December 31, 2019 | 5.034M |
| September 30, 2019 | 21.33M |
| June 30, 2019 | 15.55M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 9.872M |
| Date | Value |
|---|---|
| September 30, 2018 | -0.019M |
| June 30, 2018 | 0.057M |
| March 31, 2018 | 0.294M |
| December 31, 2017 | 1.056M |
| September 30, 2017 | 0.453M |
| June 30, 2017 | 5.489M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | -0.006M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.006M |
| December 31, 2015 | -26.01M |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.013M |
| March 31, 2015 | 27.90M |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 35.36M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 21.92M |
| March 31, 2013 | 0.115M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-27.36M
Minimum
Mar 2023
187.22M
Maximum
Sep 2020
23.38M
Average
0.514M
Median
Cash from Financing (Quarterly) Benchmarks
| Bioventus Inc | 0.362M |
| Fulcrum Therapeutics Inc | 0.635M |
| Pfizer Inc | -4.636B |
| AIM ImmunoTech Inc | 0.137M |
| Protalix BioTherapeutics Inc | -20.42M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -23.76M |
| Cash from Investing (Quarterly) | -0.08M |
| Free Cash Flow | -61.62M |
| Free Cash Flow Per Share (Quarterly) | -0.8811 |
| Free Cash Flow to Equity (Quarterly) | -23.84M |
| Free Cash Flow to Firm (Quarterly) | -23.84M |
| Free Cash Flow Yield | -13.53% |